EMBRACA Phase 3 trial

June 26, 2019

European Commission Approves Talzenna to Treat Some Breast Cancers

News

The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy ... Read more

October 19, 2018

FDA Approves Talzenna to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Talzenna (talazoparib) for the treatment of HER2-negative advanced breast cancer in adult patients with inherited BRCA mutations. The FDA also stated that patients’ eligibility for ... Read more

June 15, 2018

Talazoparib, Potential Treatment for Metastatic Breast Cancer with BRCA Mutations, Up for US and EU Approval

News

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review Pfizer’s application for talazoparib, a candidate for the treatment of metastatic breast cancer in patients ... Read more